Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment
Anaplastic large cell lymphoma (ALCL) is an uncommon type of non-Hodgkin’s lymphoma (NHL), as well as one of the subtypes of T cell lymphoma, accounting for 1 to 3% of non-Hodgkin’s lymphomas and around 15% of T cell lymphomas. In 2016, the World Health Organization (WHO) classified anaplastic large...
Main Authors: | Xin-Rui Zhang, Pham-Ngoc Chien, Sun-Young Nam, Chan-Yeong Heo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/7/1650 |
Similar Items
-
The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
by: Ivonne A. Montes-Mojarro, et al.
Published: (2018-04-01) -
From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
by: Michael T. Werner, et al.
Published: (2017-10-01) -
Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma—Experience from an Indian Center
by: Muthiah Vaikundaraja Indhuja, et al. -
ALK signaling and target therapy in anaplastic large cell lymphoma
by: Fabrizio eTabbo, et al.
Published: (2012-05-01) -
An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
by: Suzanne D. Turner
Published: (2017-10-01)